ID   RIPK1_HUMAN             Reviewed;         671 AA.
AC   Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 3.
DT   02-NOV-2010, entry version 113.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Cell death protein RIP;
DE   AltName: Full=Receptor-interacting protein 1;
DE            Short=RIP-1;
DE   AltName: Full=Serine/threonine-protein kinase RIP;
GN   Name=RIPK1; Synonyms=RIP, RIP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1; TRAF2 AND TRAF3,
RP   AND VARIANT VAL-438.
RC   TISSUE=Umbilical vein endothelial cell;
RX   MEDLINE=96200892; PubMed=8612133; DOI=10.1016/S1074-7613(00)80252-6;
RA   Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.;
RT   "TNF-dependent recruitment of the protein kinase RIP to the TNF
RT   receptor-1 signaling complex.";
RL   Immunity 4:387-396(1996).
RN   [2]
RP   SEQUENCE REVISION TO 120.
RA   Huang J., Hsu H., Baichwal V.R., Goeddel D.V.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2).
RC   TISSUE=Adrenal gland, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-438.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438.
RC   TISSUE=Leukemic T-cell;
RX   MEDLINE=95277838; PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [9]
RP   CLEAVAGE BY CASPASE-8, AND MUTAGENESIS OF ASP-324.
RX   MEDLINE=99452794; PubMed=10521396; DOI=10.1101/gad.13.19.2514;
RA   Lin Y., Devin A., Rodriguez Y., Liu Z.-G.;
RT   "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-
RT   induced apoptosis.";
RL   Genes Dev. 13:2514-2526(1999).
RN   [10]
RP   INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [11]
RP   INTERACTION WITH RIPK3.
RX   MEDLINE=99287880; PubMed=10358032; DOI=10.1074/jbc.274.24.16871;
RA   Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.;
RT   "RIP3, a novel apoptosis-inducing kinase.";
RL   J. Biol. Chem. 274:16871-16875(1999).
RN   [12]
RP   INTERACTION WITH BNLF1.
RX   MEDLINE=99340272; PubMed=10409763;
RA   Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B.,
RA   Kieff E.D.;
RT   "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages
RT   the tumor necrosis factor receptor-associated proteins TRADD and
RT   receptor-interacting protein (RIP) but does not induce apoptosis or
RT   require RIP for NF-kappaB activation.";
RL   Mol. Cell. Biol. 19:5759-5767(1999).
RN   [13]
RP   INTERACTION WITH IKBKG.
RX   MEDLINE=99128359; PubMed=9927690; DOI=10.1073/pnas.96.3.1042;
RA   Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A.,
RA   Wallach D., Horwitz M.S.;
RT   "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB
RT   activity and as a target of an adenovirus inhibitor of tumor necrosis
RT   factor alpha-induced apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999).
RN   [14]
RP   INTERACTION WITH EGFR.
RX   MEDLINE=21153697; PubMed=11116146; DOI=10.1074/jbc.M008458200;
RA   Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S.,
RA   Vartanian T.;
RT   "The epidermal growth factor receptor engages receptor interacting
RT   protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to
RT   activate NF-kappa B. Identification of a novel receptor-tyrosine
RT   kinase signalosome.";
RL   J. Biol. Chem. 276:8865-8874(2001).
RN   [15]
RP   INTERACTION WITH RNF216.
RX   MEDLINE=21975204; PubMed=11854271; DOI=10.1074/jbc.M108675200;
RA   Chen D., Li X., Zhai Z., Shu H.-B.;
RT   "A novel zinc finger protein interacts with receptor-interacting
RT   protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-
RT   induced NF-kappa B activation.";
RL   J. Biol. Chem. 277:15985-15991(2002).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384; TYR-387 AND
RP   SER-389, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [17]
RP   INTERACTION WITH ZFAND5.
RX   PubMed=14754897; DOI=10.1074/jbc.M309491200;
RA   Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z.,
RA   Shu H.-B.;
RT   "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor
RT   of NFkappaB activation.";
RL   J. Biol. Chem. 279:16847-16853(2004).
RN   [18]
RP   UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3.
RX   PubMed=15258597; DOI=10.1038/nature02794;
RA   Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S.,
RA   Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V.,
RA   Dixit V.M.;
RT   "De-ubiquitination and ubiquitin ligase domains of A20 downregulate
RT   NF-kappaB signalling.";
RL   Nature 430:694-699(2004).
RN   [19]
RP   INTERACTION WITH MAVS.
RX   PubMed=16127453; DOI=10.1038/ni1243;
RA   Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H.,
RA   Ishii K.J., Takeuchi O., Akira S.;
RT   "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I
RT   interferon induction.";
RL   Nat. Immunol. 6:981-988(2005).
RN   [20]
RP   UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377.
RX   PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026;
RA   Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.;
RT   "Activation of IKK by TNFalpha requires site-specific ubiquitination
RT   of RIP1 and polyubiquitin binding by NEMO.";
RL   Mol. Cell 22:245-257(2006).
RN   [21]
RP   REVIEW.
RX   PubMed=17301840; DOI=10.1038/sj.cdd.4402085;
RA   Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.;
RT   "RIP1, a kinase on the crossroads of a cell's decision to live or
RT   die.";
RL   Cell Death Differ. 14:400-410(2007).
RN   [22]
RP   INTERACTION WITH RBCK1.
RX   PubMed=17449468; DOI=10.1074/jbc.M701913200;
RA   Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P.,
RA   Zhang M., Chen D.Y., Zhai Z.H., Shu H.B.;
RT   "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-
RT   triggered NF-kappaB activation by targeting TAB2/3 for degradation.";
RL   J. Biol. Chem. 282:16776-16782(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404;
RP   VAL-443 AND VAL-569.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Essential adapter molecule for the activation of NF-
CC       kappa-B. Following different upstream signals (binding of
CC       inflammatory cytokines, stimulation of pathogen recognition
CC       receptors, or DNA damage), particular RIPK1-containing complexes
CC       are formed, initiating a limited number of cellular responses.
CC       Upon TNFA stimulation RIPK1 is recruited to a TRADD-TRAF complex
CC       initiated by TNFR1 trimerization. There, it is ubiquitinated via
CC       'Lys-63'-link chains, inducing its association with the IKK
CC       complex, and its activation through NEMO binding of polyubiquitin
CC       chains.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Binds to the death domain of TNFRSF6 and TRADD. Is
CC       recruited by TRADD to TNFRSF1A in a TNF-dependent process. Binds
CC       RIPK3, RNF216 isoform 3 (ZIN), EGFR, IKBKG, TRAF1, TRAF2 and
CC       TRAF3. Interacts with BNLF1. Interacts with SQSTM1 upon TNF-alpha
CC       stimulation. May interact with MAVS/IPS1. Interacts with ZFAND5.
CC       Interacts with RBCK1.
CC   -!- INTERACTION:
CC       Q14790:CASP8; NbExp=1; IntAct=EBI-358507, EBI-78060;
CC       Q8IVM0:CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996;
CC       P48729:CSNK1A1; NbExp=4; IntAct=EBI-358507, EBI-1383726;
CC       Q13158:FADD; NbExp=1; IntAct=EBI-358507, EBI-494804;
CC       Q9Y6K9:IKBKG; NbExp=1; IntAct=EBI-358507, EBI-81279;
CC       Q07174:Map3k8 (xeno); NbExp=1; IntAct=EBI-358507, EBI-309771;
CC       P25799:Nfkb1 (xeno); NbExp=1; IntAct=EBI-358507, EBI-643958;
CC       Q9Y572:RIPK3; NbExp=5; IntAct=EBI-358507, EBI-298250;
CC       P19438:TNFRSF1A; NbExp=1; IntAct=EBI-358507, EBI-299451;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13546-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13546-2; Sequence=VSP_037690;
CC         Note=No experimental confirmation available;
CC   -!- PTM: Proteolytically cleaved by caspase-8 during TNF-induced
CC       apoptosis. Cleavage abolishes NF-kappa-B activation and enhances
CC       pro-apototic signaling through the TRADD-FADD interaction.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC   -!- PTM: Ubiquitinated. Polyubiquitination with 'Lys-63'-linked chains
CC       by TRAF2 induces association with the IKK complex.
CC       Deubiquitination of 'Lys-63'-linked chains and polyubiquitination
CC       with 'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteosomal
CC       degradation and consequently to the termination of the TNF- or
CC       LPS-mediated activation of NF-kappa-B.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 1 death domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG65471.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ripk1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U50062; AAC32232.1; -; mRNA.
DR   EMBL; AK314176; BAG36858.1; -; mRNA.
DR   EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA.
DR   EMBL; AY682848; AAT74626.1; -; Genomic_DNA.
DR   EMBL; AL031963; CAD70625.1; -; Genomic_DNA.
DR   EMBL; BC126254; AAI26255.1; -; mRNA.
DR   EMBL; BC126256; AAI26257.1; -; mRNA.
DR   EMBL; AB208926; BAD92163.1; -; mRNA.
DR   EMBL; U25994; AAC50137.1; -; mRNA.
DR   IPI; IPI00013773; -.
DR   IPI; IPI00939198; -.
DR   PIR; T09479; T09479.
DR   RefSeq; NP_003795.2; -.
DR   UniGene; Hs.519842; -.
DR   ProteinModelPortal; Q13546; -.
DR   SMR; Q13546; 13-291, 578-666.
DR   DIP; DIP-433N; -.
DR   IntAct; Q13546; 54.
DR   MINT; MINT-128219; -.
DR   STRING; Q13546; -.
DR   PhosphoSite; Q13546; -.
DR   PRIDE; Q13546; -.
DR   Ensembl; ENST00000259808; ENSP00000259808; ENSG00000137275.
DR   Ensembl; ENST00000380409; ENSP00000369773; ENSG00000137275.
DR   GeneID; 8737; -.
DR   KEGG; hsa:8737; -.
DR   UCSC; uc003mux.1; human.
DR   CTD; 8737; -.
DR   GeneCards; GC06P003064; -.
DR   H-InvDB; HIX0005535; -.
DR   HGNC; HGNC:10019; RIPK1.
DR   HPA; CAB010302; -.
DR   HPA; HPA015257; -.
DR   MIM; 603453; gene.
DR   PharmGKB; PA34394; -.
DR   eggNOG; prNOG05953; -.
DR   HOGENOM; HBG445889; -.
DR   HOVERGEN; HBG055612; -.
DR   InParanoid; Q13546; -.
DR   OMA; SHDPFAQ; -.
DR   OrthoDB; EOG9VDSJ8; -.
DR   PhylomeDB; Q13546; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; caspase_pathway; Caspase cascade in apoptosis.
DR   Pathway_Interaction_DB; ceramidepathway; Ceramide signaling pathway.
DR   Pathway_Interaction_DB; faspathway; FAS signaling pathway (CD95).
DR   Pathway_Interaction_DB; hivnefpathway; HIV-1 Nef: Negative effector of Fas and TNF-alpha.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; tnfpathway; TNF receptor signaling pathway.
DR   Pathway_Interaction_DB; trail_pathway; TRAIL signaling pathway.
DR   Reactome; REACT_578; Apoptosis.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 32775; -.
DR   PMAP-CutDB; Q13546; -.
DR   ArrayExpress; Q13546; -.
DR   Bgee; Q13546; -.
DR   CleanEx; HS_RIPK1; -.
DR   Genevestigator; Q13546; -.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0070513; F:death domain binding; IPI:BHF-UCL.
DR   GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:BHF-UCL.
DR   GO; GO:0008633; P:activation of pro-apoptotic gene products; EXP:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB cascade; EXP:Reactome.
DR   GO; GO:0006917; P:induction of apoptosis; IMP:BHF-UCL.
DR   GO; GO:0060555; P:induction of necroptosis by extracellular s...; IMP:BHF-UCL.
DR   GO; GO:0045768; P:positive regulation of anti-apoptosis; TAS:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-k...; IEP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcript...; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0070926; P:regulation of ATP:ADP antiporter activity; IMP:BHF-UCL.
DR   GO; GO:0080010; P:regulation of oxygen and reactive oxygen sp...; TAS:BHF-UCL.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pa...; IC:BHF-UCL.
DR   InterPro; IPR000488; Death.
DR   InterPro; IPR011029; DEATH-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Gene3D; G3DSA:1.10.533.10; DEATH_like; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00005; DEATH; 1.
DR   SUPFAM; SSF47986; DEATH_like; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Complete proteome;
KW   Cytoplasm; Isopeptide bond; Kinase; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    671       Receptor-interacting serine/threonine-
FT                                protein kinase 1.
FT                                /FTId=PRO_0000086606.
FT   DOMAIN       17    289       Protein kinase.
FT   DOMAIN      583    669       Death.
FT   NP_BIND      23     31       ATP (By similarity).
FT   REGION      290    582       Interaction with SQSTM1.
FT   COMPBIAS    411    414       Poly-Arg.
FT   ACT_SITE    138    138       Proton acceptor (By similarity).
FT   BINDING      49     49       ATP (By similarity).
FT   SITE        324    325       Cleavage; by caspase-8.
FT   MOD_RES     320    320       Phosphoserine.
FT   MOD_RES     384    384       Phosphotyrosine.
FT   MOD_RES     387    387       Phosphotyrosine.
FT   MOD_RES     389    389       Phosphoserine.
FT   CROSSLNK    377    377       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VAR_SEQ     108    153       Missing (in isoform 2).
FT                                /FTId=VSP_037690.
FT   VARIANT      64     64       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041039.
FT   VARIANT      81     81       V -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041040.
FT   VARIANT     220    220       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041041.
FT   VARIANT     234    234       E -> K (in dbSNP:rs17548383).
FT                                /FTId=VAR_021109.
FT   VARIANT     404    404       A -> S (in dbSNP:rs34872409).
FT                                /FTId=VAR_041042.
FT   VARIANT     438    438       A -> V (in dbSNP:rs3173519).
FT                                /FTId=VAR_058285.
FT   VARIANT     443    443       A -> V (in dbSNP:rs35722193).
FT                                /FTId=VAR_041043.
FT   VARIANT     569    569       A -> V (in dbSNP:rs55861377).
FT                                /FTId=VAR_041044.
FT   MUTAGEN      45     45       K->A: Abolishes kinase activity.
FT   MUTAGEN     324    324       D->K: Abolishes cleavage by caspase-8.
FT   MUTAGEN     377    377       K->R: Abolishes RIP-mediated NF-Kappa-B
FT                                activation.
FT   CONFLICT    258    258       R -> I (in Ref. 3; BAG36858).
FT   CONFLICT    286    286       R -> S (in Ref. 3; BAG36858).
FT   CONFLICT    514    514       T -> S (in Ref. 8; AAC50137).
SQ   SEQUENCE   671 AA;  75931 MW;  976E2428D525A9B2 CRC64;
     MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL
     LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL
     EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD
     GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC
     IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED
     VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA
     PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF
     AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD
     PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ
     IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN
     CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID
     LLSSLIYVSQ N
//
